Agios Makes Case For Pyrukynd Approval In SCD Despite Mixed Phase III Results

Hemoglobin Responders Had Meaningful Pain, Fatigue Improvements

 
• By Mandy Jackson
  
Pyrukynd significantly improved hemolysis in sickle cell disease, but did not significantly reduce pain events (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Scrip

More from Strategy